Report: Celtics Still Considering Two More Offseason Trades
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Brad Stevens and the Boston Celtics have been busy this offseason. Due to the torn Achilles injury suffered by Jayson Tatum and the team's luxury tax situation, the Celtics were forced to trade away two of their main pieces early on in the offseason.
First, the team made a big trade with the Portland Trail Blazers to ship out veteran star guard Jrue Holiday. Boston received Anfernee Simons in return as the centerpiece of the deal.
After that move, the Celtics made a trade to send Kristaps Porzingis to the Atlanta Hawks. Georges Niang was the main piece received back in that trade.
Head coach Brad Stevens of the Boston Celtics looks on against the Brooklyn Nets in Game One of the First Round of the 2021 NBA Playoffs at Barclays Center at Barclays Center on May 22,...
Head coach Brad Stevens of the Boston Celtics looks on against the Brooklyn Nets in Game One of the First Round of the 2021 NBA Playoffs at Barclays Center at Barclays Center on May 22, 2021 in New York City. More
Photo byWhile those two moves were major changes for the franchise, they might not be done yet.
Read more: Report: Celtics Miss Out on Top-Tier Offseason Target
According to a report from NBA insider Jake Fischer, Boston is still showing interest in two other potential trades this offseason.
"As we discussed, I think the Celtics are still very active in taking trade calls—maybe even making trade calls. There was some conversation last week between Memphis and Boston about something. We're still looking to track down more info on that. But rival teams are definitely still under the impression that Boston is looking for deals involving both Anfernee Simons and Georges Niang," Fischer said.
Simons is currently owed over $27.6 million in the final year of his contract. He could be moved to save more financially, but Stevens did speak out recently and talk about the 26-year-old's future and potential fit with the team.
"Anfernee is a guy people out here probably don't see as much because of the time that they play," Stevens said. "But his ability to score, to shoot the ball, make really hard shots, is pretty elite. And you look, a guy that's 26 years old and averaged 20 a game for three straight years."
Read more: Report: Lakers May Face Luka Doncic Threat From Western Conference Rival
As for Niang, he has just one year left on his contract as well worth $8.2 million.
Of course, no one truly knows what a team is going to do. The Celtics could very well head into the 2025-26 season with both Simons and Niang on the roster.
Expect to continue hearing rumors surrounding Boston. At the very least, the Celtics are a team worth keeping an eye on as a franchise potentially still open for business.
For more on the Boston Celtics and general NBA news, head on over to Newsweek Sports.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease." About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
44 minutes ago
- USA Today
Boston Celtics jersey history No. 27 - Daniel Theis (2017-21, 2022-23)
The Boston Celtics have had players suiting up in a total of 68 different jersey numbers (and have three others not part of any numerical series) since their founding at the dawn of the Basketball Association of America (BAA -- the league that would become today's NBA), worn by well over 500 players in the course of Celtics history. To commemorate the players who wore those numbers, Celtics Wire is covering the entire history of jersey numbers and the players who sported them since the founding of the team. With 25 of those jerseys now retired to honor some of the greatest Celtics to wear those jerseys, there is a lot of history to cover. And for today's article, we will continue with the 12th of 13 people to wear the No. 27, Boston big man alum Daniel Theis. After starting his pro career abroad, Theis would go unselected in the 2013 NBA Draft, Theis would sign with the Celtics in 2017 for the first of two stints. That first stint ended in 2021 with a trade to the Chicago Bulls, with Theis playing for the Houston Rockets as well before being dealt by them back to Boston in 2022 for the rest of the 2021-22 season, and was traded again, this time to the Indiana Pacers in 2023. During his time suiting up for the Celtics, Theis wore only jersey No. 27 and put up 7.3 points, 4.8 rebounds, and 1.3 assists per game. All stats and data courtesy of Basketball Reference.
Newsweek
2 hours ago
- Newsweek
Why Red Sox Need This Trade Upgrade For Second Consecutive Season
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Boston Red Sox are in position to buy at the MLB trade deadline despite a 2-4 slump against top talent coming out of the All-Star break. A frontline starting pitcher and a first baseman are the main priorities for Boston, but it's clear another position to needs to be upgraded for the second consecutive summer. BOSTON, MASSACHUSETTS - JULY 2: Connor Wong #12 of the Boston Red Sox hits a single during the second inning of a game against the Cincinnati Reds on July 2, 2025 at Fenway Park in... BOSTON, MASSACHUSETTS - JULY 2: Connor Wong #12 of the Boston Red Sox hits a single during the second inning of a game against the Cincinnati Reds on July 2, 2025 at Fenway Park in Boston, Massachusetts. More Photo by Maddie Malhotra/Boston/Getty Images Boston moved on from backup catcher Reese McGuire last summer and traded for Toronto Blue Jays catcher Danny Jansen to pair with Connor Wong, who found a surge in his bat. This year, Carlos Narvaez outplayed Wong to win the starting job following an offseason trade with the New York Yankees. Narvaez continues to pace MLB backstops in runners caught stealing and defensive runs saved, though he's manned a heavy workload through the first 100 games of the season. The Red Sox have gotten next to nothing from Wong, who is yet to deliver a hit with runners in scoring position. He has just one run driven in this season to the tune of a .372 OPS. It won't take much for Boston to earn an upgrade and the market isn't loaded. If the chance comes around, for the sake of Narvaez's help, the Red Sox need to be proactive behind the plate. More MLB: Yankees Have Competition From 11 Teams For All-Star Third Baseman: Report
